Argireline (acetyl hexapeptide-8): what the research shows
- By Reed Calder
- Last reviewed Nov 12, 2026
- 27 studies and official documents checked
In short
Argireline is a lab-made peptide of six amino acids, sold in serums as “Botox in a bottle.” It copies part of a protein that nerves need to release their signal to a muscle. In people it has been tested in a few small studies. Two reported fewer wrinkles: 10 women over 30 days (up to 30%) and 60 Chinese adults (48.9% against 0% on placebo, by eye). A blinded split-face study of 19 women found no difference between the side with Argireline and the side without it. We found no study showing that it relaxes a facial muscle in a person, and in skin tests only a small share of a 10% cream got past the outer layer. The cosmetic safety panel found it safe up to 0.005% and said the data were insufficient above that. It isn’t a drug, and it isn’t for injection.
EvidenceCellAnimalHumansmall trials; none shows muscle relaxation in people
You’ll often read that Argireline works like Botox without the needle, shows results in days, and is safe because it is gentle. This page covers what it is, what each study in people found, how deep it gets into skin, what strength was used, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| Argireline | A trademark of the ingredient’s maker, Lubrizol, for the peptide below (Lubrizol) | Yes, in small studies |
| Acetyl hexapeptide-8, acetyl hexapeptide-8 amide | The ingredient name on labels, with an amide group on the end (FDA GSRS) | Same as Argireline |
| Acetyl hexapeptide-3 | The older name for the same peptide, still used in some papers (FDA GSRS) | Same as Argireline |
| Acetyl hexapeptide-8 acid | A different substance: the same chain ending in an acid instead of an amide (FDA GSRS) | No study found |
| Argireline Amplified, Argireline YOUth | Other products from the same maker; YOUth is an oil-soluble version (Lubrizol) | No study in people found |
| SNAP-8 (acetyl octapeptide-3) | A longer, eight-amino-acid relative made for the same purpose (see the skin peptides page) | No study of it alone found |
| Injectable “Argireline” vials | Powder sold for injection | No study in people |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The amide and acid forms have different registry numbers.
What Argireline is
Argireline is the peptide Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2. It is patterned on the end of SNAP-25, a protein that helps nerve cells release the chemical signal that tells a muscle to contract (Wang et al., 2013; Blanes-Mira et al., 2002). It was designed as a non-toxic copy of the way botulinum toxin acts (Blanes-Mira et al., 2002). Its maker says it was launched in 2001 (Lubrizol).
In cell experiments, the peptide blocked the release of that signal with a potency similar to botulinum toxin A, but with much lower efficacy (Blanes-Mira et al., 2002). Cells in a dish aren’t a face. Whether enough peptide reaches a nerve ending in living skin is the open question below.
What has been studied
In people: wrinkles
- 10 women, 2002. An emulsion with 10% of the peptide cut wrinkle depth by up to 30% over 30 days, measured on skin imprints (Blanes-Mira et al., 2002). A 2023 paper says this study had 10 women, that the plain emulsion cut depth by up to 10%, and that it used an unusually loose significance threshold of p below 0.075 (Henseler, 2023).
- 60 Chinese adults, 2013. Argireline or placebo, split 3 to 1, was applied twice a day to the wrinkles around the eyes for 4 weeks. The researchers’ “total anti-wrinkle efficacy” score was 48.9% on Argireline and 0% on placebo. Roughness measured on skin imprints fell on Argireline (p below 0.01) and not on placebo (Wang et al., 2013). The 2023 paper points out that the main result came from 4- and 5-point scores judged by eye (Henseler, 2023).
- 19 women, blinded split face, 2023. For 4 weeks both sides of the face got the same hyaluronic acid serum, and one side’s serum also held Argireline. A camera system scored wrinkles. Both sides improved slightly, not significantly, and the two sides did not differ (p = 0.829). The author, who reports no competing interests, concluded the effect was not proven. The serum strength isn’t given, and the women kept using their own skin care (Henseler, 2023).
- 24 volunteers in four groups, 2017. Over 60 days, groups used acetyl hexapeptide-3, tripeptide-10 citrulline, both, or neither. Some skin-surface and water-loss measures differed between groups, and the authors say it confirms antiwrinkle activity. The groups were very small (Raikou et al., 2017).
- 26 patients, no control group, 2020. A retrospective look at a 10% gel-cream used on scars and skin imperfections found better skin values and no allergic reactions (Palmieri et al., 2020).
- Registered, never published. A 70-person trial of an Argireline gel for wrinkles around the eyes finished in 2009 and a 14-person split-face trial of a 10% lotion for oily skin in 2016. Neither posted results, and we found no paper (NCT01381484; NCT02597777).
With a delivery aid or in a mixed product
- Microneedle patch, 2019. In 52 Korean women, a dissolving patch alone, with Argireline, or with a growth factor was compared in a blinded split-face trial, applied once a week for 29 days. All three improved; the Argireline patch beat the plain patch for wrinkles (p below 0.05) (An et al., 2019).
- Five-ingredient serum, 2026. Two single-arm studies of 50 and 42 women found better wrinkle scores over 12 weeks. There was no control group, so Argireline can’t be separated from the other four ingredients (Zhu et al., 2026).
The one test on a muscle
- Eyelid spasm, 2013. In 24 patients with blepharospasm who had botulinum toxin injections, a daily Argireline product or placebo was started after each injection. Symptoms took 3.7 months to return on Argireline and 3.0 on placebo, which the authors call a trend. Four of 12 on Argireline had a long extension, 3.3 to 7.1 months. No significant side effects (Lungu et al., 2013; NCT00942851). A follow-up trial of 0.05% and 0.025% creams against placebo stopped after 8 patients (NCT01750346).
EvidenceCellAnimalHumansmall trials; none shows muscle relaxation in people
In animals
- Mice, applied to skin. In aged mice, Argireline twice a day for 6 weeks raised type I collagen fibers and lowered type III (Wang et al., 2013).
- Rats, injected. In 40 rats given injections under the skin, Argireline alone left the collagen profile “indistinguishable from control” and had no detectable tissue-level effect (Acuner et al., 2026).
EvidenceCellAnimalHuman
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| It works like Botox | Contradicted | In cells it blocked the nerve signal with much lower efficacy than botulinum toxin A (Blanes-Mira et al., 2002). A 2025 review found that none of the skin-application studies it covered confirmed inhibition of muscle contraction (Zdrada-Nowak et al., 2025). The blinded split-face author concluded it is not an alternative to botulinum toxin (Henseler, 2023) |
| It cuts wrinkles by 30% or 49% | Mixed | Those figures are real and come from 10 women with a loose significance threshold and from eye-scored grades in a 3-to-1 split (Blanes-Mira et al., 2002; Wang et al., 2013; Henseler, 2023). The one blinded camera study found no difference between sides |
| Results in hours or a week | Untested | The Argireline-alone trials measured at 4 weeks or later (Wang et al., 2013; Henseler, 2023). A single-arm study of a five-ingredient serum reported change in week 1 (Zhu et al., 2026), and a maker’s page cites 20.6% in one week with a 2% solution without naming a study (Lubrizol) |
| It prevents new wrinkles | Untested | We found no study that measured prevention |
| It reaches the muscle | Untested | In skin tests most of a 10% cream washed off and about 0.22% stayed in the outer layer of human skin (Kraeling et al., 2015). A 2025 review calls its ability to reach the nerve-muscle junction uncertain (Zdrada-Nowak et al., 2025) |
| It extends the effect of Botox | Mixed | In 24 eyelid-spasm patients, symptom control lasted 3.7 months against 3.0, a trend (Lungu et al., 2013). Nothing like this has been tested for wrinkles |
| It is safe and has no side effects | Mixed | No significant side effects in the small trials (Henseler, 2023; Lungu et al., 2013). The safety panel found it safe only up to 0.005% and the data insufficient above that (Johnson et al., 2025) |
| Injecting it works better | Untested | No study in people. In rats it had no detectable tissue effect (Acuner et al., 2026), and a woman developed a serious infection after facial injections (Chen et al., 2021) |
| It beats retinol, or works best with other peptides | Untested | We found no trial comparing it with retinoids, and none with collagen-signal peptides such as Matrixyl. The one trial that paired it with another peptide had a few people per group (Raikou et al., 2017) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the strengths mean
Labels and studies use very different numbers, and the label usually doesn’t say what the number is a percentage of.
| Where | Strength | What it was |
|---|---|---|
| Blanes-Mira et al., 2002 | 10% of the peptide | Cream on women, 30 days |
| Kraeling et al., 2015 | 10% in an emulsion | Skin penetration test, 24 hours |
| Palmieri et al., 2020 | 10% gel-cream | 26 patients, no control group |
| NCT02597777 | 10% lotion | Split-face trial, 14 people, no results |
| Zdrada-Nowak et al., 2025 | Describes the 2013 Chinese trial as 10% | The trial’s abstract gives no strength |
| NCT01750346 | 0.05% and 0.025% | Eyelid-spasm trial stopped at 8 patients |
| Henseler, 2023 | Not stated | Blinded split-face study, 19 women |
| Johnson et al., 2025 | Safe up to 0.005%; data insufficient above | Cosmetic safety panel |
| Lubrizol | Recommended use level 2 to 10% | The maker’s solution; the page doesn’t give its peptide content |
If the figure on a serum is a percentage of the peptide, 10% is 2,000 times the strength the safety panel reviewed as safe. If it is a percentage of a diluted solution, it may be far less. The pages we read don’t say which, so neither the studies’ results nor the panel’s limit can be matched to a product. These are strengths from studies, not advice for anyone to use.
How much gets into the skin
- Most stays on top. After 24 hours on skin from a hairless guinea pig and from human cadavers, most of a 10% cream washed off. What went in stayed mostly in the outer dead layer: 0.54% in guinea pig and 0.22% in human skin. The living epidermis held 0.01% (Kraeling et al., 2015).
- The base matters. In pig skin, a water-in-oil-in-water emulsion delivered significantly more than simple emulsions (Hoppel et al., 2015).
- Review verdict. The peptide is large and water-loving, so it has “limited permeability” through the skin’s outer layer, and its ability to reach the nerve-muscle junction “remains uncertain” (Zdrada-Nowak et al., 2025).
- Microneedles helped. A dissolving patch with Argireline beat the plain patch in a split-face trial (An et al., 2019), which is one sign that delivery matters.
Side effects and safety
- The safety panel’s limit. The Expert Panel for Cosmetic Ingredient Safety concluded acetyl hexapeptide-8 is safe in cosmetics at concentrations up to 0.005%, and that the data are insufficient to say it is safe above 0.005% (Johnson et al., 2025). That is a gap in the data, not a finding of harm.
- In the small trials. No significant adverse events in 24 eyelid-spasm patients or in 19 women using a serum for 4 weeks, and no allergic reactions in 26 patients (Lungu et al., 2013; Henseler, 2023; Palmieri et al., 2020).
- Injected. A 45-year-old woman who had acetyl hexapeptide-8 injected in the forehead and temples developed nodules and abscesses within a week. The cause was Mycobacterium abscessus, and she needed two antibiotics for 5 months (Chen et al., 2021).
- What is in the bottle. A lab found both the peptide and an oxidized form of it in several creams and serums (Kluczyk et al., 2021).
- Not studied. Pregnancy, children, long-term daily use, and strengths above the panel’s limit.
Side effects people report from online products aren’t covered here; they come from users, not studies.
Legal and approval status
- Not an approved drug. It is sold as a cosmetic ingredient, and cosmetics don’t need FDA approval (FDA, 2025).
- Not on the FDA’s lists. It doesn’t appear on the FDA’s safety-risk page or in its May 2026 compounding categories (FDA, 2026; FDA list, May 2026). That is not an approval.
- Registered trials. ClinicalTrials.gov lists seven studies, two with posted results, and we found none that shows it relaxes a muscle (ClinicalTrials.gov search).
- Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
- Not named on the World Anti-Doping Agency’s 2026 list (WADA, 2026).
- “Research use only” powders and any injectable use aren’t approved.
What to look for if you research it
We don’t name or link sellers. These checks come from the studies:
- The ingredient name. Look for acetyl hexapeptide-8, or the older acetyl hexapeptide-3. “Argireline” is a brand name, and the amide and acid forms are different substances (FDA GSRS; FDA GSRS).
- A percentage of what. Ask whether a figure such as 10% is the peptide or a diluted solution of it (see the strengths above).
- The intact peptide. A lab report should show the intact peptide, since oxidized forms turn up in products (Kluczyk et al., 2021).
- A fair comparison. The studies to trust split the face or used a placebo and measured with a camera or skin imprints, as in the blinded split-face study (Henseler, 2023). Before-and-after photos can’t separate the peptide from the moisturizing base.
- Not for injection. There is no study of it in people, and one report of a serious infection (Chen et al., 2021).
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite. For other skin peptides, see peptides for skin.
What’s still unknown
- Whether any skin product relaxes a facial muscle in a person.
- Whether the 30% and 49% results hold up when scored blind with a camera.
- What the peptide percentage on a serum means, and whether any serum matches a studied strength.
- Whether it is safe above the 0.005% the safety panel reviewed.
- Whether it does anything beyond what the moisturizing base does.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Argireline. We recheck every month. Last checked Nov 12, 2026.
We found no retracted, withdrawn or flagged studies that mention Argireline.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Blanes-Mira et al., 2002 | Int J Cosmet Sci | No retraction or concern |
| Lungu et al., 2013 | Eur J Neurol | No retraction or concern |
| Wang et al., 2013 | Am J Clin Dermatol | No retraction or concern |
| Wang et al., 2013 | J Cosmet Laser Ther | No retraction or concern |
| Kraeling et al., 2015 | Cutan Ocul Toxicol | No retraction or concern |
| Hoppel et al., 2015 | Eur J Pharm Sci | No retraction or concern |
| Raikou et al., 2017 | J Cosmet Dermatol | No retraction or concern |
| Palmieri et al., 2020 | Clin Ter | No retraction or concern |
| Kluczyk et al., 2021 | Chem Biodivers | No retraction or concern |
| Chen et al., 2021 | World J Clin Cases | No retraction or concern |
| An et al., 2019 | Ann Dermatol | No retraction or concern |
| Henseler, 2023 | GMS Interdiscip Plast Reconstr Surg DGPW | No retraction or concern |
| Zdrada-Nowak et al., 2025 | Int J Mol Sci | No retraction or concern |
| Johnson et al., 2025 | Int J Toxicol | No retraction or concern |
| Zhu et al., 2026 | Int J Cosmet Sci | No retraction or concern |
| Acuner et al., 2026 | Aesthetic Plast Surg | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is Argireline?
A lab-made peptide of six amino acids, patterned on part of a nerve-signalling protein, used in wrinkle serums. Its ingredient name is acetyl hexapeptide-8 (Wang et al., 2013; FDA GSRS).
What does Argireline do to the skin?
In small trials, wrinkle scores improved, but the one blinded split-face study found no difference from the same serum without it (Wang et al., 2013; Henseler, 2023).
Is Argireline really Botox in a bottle?
We found no study showing that it relaxes a muscle in a person, and in cells it was far weaker than botulinum toxin (Blanes-Mira et al., 2002; Zdrada-Nowak et al., 2025).
Does Argireline work?
It is unproven. Two small older studies found fewer wrinkles, and the one blinded camera study didn’t (Blanes-Mira et al., 2002; Wang et al., 2013; Henseler, 2023).
How long does Argireline take to work?
The Argireline-alone trials measured at 4 weeks or later. A five-ingredient serum with no control group reported change in week 1, and we found no study showing results in hours (Wang et al., 2013; Henseler, 2023; Zhu et al., 2026).
What do Argireline before-and-after photos show?
Not much by themselves. In the blinded split-face study, wrinkle scores fell slightly on both sides, with and without Argireline, so a photo can’t separate the peptide from the base (Henseler, 2023).
What are the side effects of Argireline?
None significant in the small trials (Henseler, 2023; Lungu et al., 2013). The safety panel’s review covers up to 0.005% (Johnson et al., 2025).
Is Argireline safe?
On skin at studied strengths, no serious problems were reported. The safety panel said it is safe up to 0.005% and the data are insufficient above that (Johnson et al., 2025). Injected, it was linked to a serious infection (Chen et al., 2021).
Is Argireline better than retinol?
We found no trial comparing them. Retinol has a longer record in skin research; this page covers only Argireline.
Argireline vs Matrixyl: which is better?
No trial compared them. They are proposed to do different jobs, Argireline on the nerve signal and Matrixyl-type peptides on collagen, and the one trial that paired Argireline with another peptide had a few people per group (Raikou et al., 2017).
What should you avoid using with Argireline?
We found no study of Argireline with other ingredients, so no combination has been shown safe or unsafe. One lab found oxidized peptide in products (Kluczyk et al., 2021).
What is the difference between Argireline, acetyl hexapeptide-8 and acetyl hexapeptide-3?
They are the same peptide. Argireline is the maker’s trade name, and acetyl hexapeptide-3 is the older ingredient name (FDA GSRS).
What strength of Argireline do studies use?
Studies in people that state a strength mostly used 10% of the peptide; a trial in eyelid spasm registered 0.05% and 0.025%. The safety panel reviewed up to 0.005% (Blanes-Mira et al., 2002; NCT01750346; Johnson et al., 2025). We don’t give dosing advice.
Does Argireline get through the skin?
Very little. Most of a 10% cream washed off, and about 0.22% stayed in the outer layer of human skin in a lab test (Kraeling et al., 2015).
Can you inject Argireline?
We found no study of injecting it in people. In rats it had no detectable tissue effect, and one woman developed a serious infection after facial injections (Acuner et al., 2026; Chen et al., 2021).
Is Argireline FDA approved or legal?
It isn’t an approved drug. It is sold as a cosmetic ingredient, which needs no FDA approval (FDA, 2025). Our guide to what to look for covers the routes people use.
Sources
- Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-10. PubMed 18498523
- Wang Y, et al. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-53. PubMed 23417317
- Henseler H. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia® Complexion Analysis camera system for objective skin analysis. GMS Interdiscip Plast Reconstr Surg DGPW. 2023;12:Doc09. PubMed 38024099
- Raikou V, et al. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Cosmet Dermatol. 2017;16(2):271-278. PubMed 28150423
- Palmieri B, et al. Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8. Clin Ter. 2020;171(6):e539-e548. PubMed 33151254
- An JH, et al. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Ann Dermatol. 2019;31(3):263-271. PubMed 33911590
- Zhu M, et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. Int J Cosmet Sci. 2026;48(5):913-925. PubMed 41668671
- Lungu C, et al. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013;20(3):515-518. PubMed 23146065
- Kraeling ME, et al. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015;34(1):46-52. PubMed 24754410
- Hoppel M, et al. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015;68:27-35. PubMed 25497319
- Zdrada-Nowak J, et al. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025;26(12):5722. PubMed 40565185
- Kluczyk A, et al. Argireline: Needle-Free Botox as Analytical Challenge. Chem Biodivers. 2021;18(3):e2000992. PubMed 33482052
- Wang Y, et al. The anti-wrinkle efficacy of Argireline. J Cosmet Laser Ther. 2013;15(4):237-41. PubMed 23464592
- Acuner B, et al. Effects of Botulinum Toxin Type A and Argireline on Dermal Collagen Remodeling and Skin Biology in a Flap Model. Aesthetic Plast Surg. 2026. PubMed 42675285
- Chen CF, et al. Mycobacterium abscessus infection after facial injection of argireline: A case report. World J Clin Cases. 2021;9(8):1996-2000. PubMed 33748252
- Johnson W, et al. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol. 2025;44(2_suppl):54S-63S. PubMed 40673537
- ClinicalTrials.gov. Search for argireline, acetyl hexapeptide-8 and acetyl hexapeptide-3, November 12, 2026: seven studies. Search
- ClinicalTrials.gov. NCT00942851: A study of acetyl hexapeptide-8 (AH8) in treatment of blepharospasm. Record
- ClinicalTrials.gov. NCT01750346: Placebo-controlled double-blind study of acetyl hexapeptide-8 in treatment of blepharospasm (terminated, 8 participants). Record
- ClinicalTrials.gov. NCT01381484: Efficacy and safety of topical Argireline in the treatment of periorbital wrinkles (completed 2009, no results posted). Record
- ClinicalTrials.gov. NCT02597777: Pilot randomized double-blind controlled trial of topical acetyl hexapeptide-8 and the cosmetic appearance of oily skin (no results posted). Record
- Lubrizol. Argireline peptides and Argireline peptide solution C (product pages, read November 12, 2026). Product page; Solution C page
- U.S. Food and Drug Administration. FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulated. Content current as of November 18, 2025. FDA page
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
- World Anti-Doping Agency. 2026 Prohibited List. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- U.S. Food and Drug Administration. Global Substance Registration System: Acetyl Hexapeptide-8 Amide (UNII L4EL31FWIL). GSRS
- U.S. Food and Drug Administration. Global Substance Registration System: Ac-Glu-Glu-Met-Gln-Arg-Arg (UNII Y7FFN3KLC6). GSRS
Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.